Study of Antitumor Efficacy of Bortezomib Combined With Temozolomide in Subcutaneous PDX Models of Human Glioblastoma

Rostorguev, E.E.; Goncharova, Anna S.; Nepomnyaschaya, E.M.; Volkova, A. V.; Zaikina, Ekaterina V.; Khodakova, D. V.

doi:10.17513/spno.30191

СПНО (MPSE)

2020

DOI: 10.17513/spno.30191

|View full text |Cite

Study of Antitumor Efficacy of Bortezomib Combined With Temozolomide in Subcutaneous PDX Models of Human Glioblastoma

E.E. Rostorguev¹,

Anna S. Goncharova²,

E.M. Nepomnyaschaya³

et al.

Abstract: the tumor growth index. By the end of the experiment, subcutaneous xenograft volumes and the tumor growth indices in the groups receiving temozolomide or bortezomib monotherapy, as well as in the temozolomide+bortezomib group, were statistically significantly lower than the corresponding values in the control group. The highest ITG% value was registered in the temozolomide+bortezomib group (85.38%); the values in groups with temozolomide and bortezomib monotherapy were 57.32% and 63.11%, respectively. Studies … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A comparative study of different contrast administration routes efficiency performed on in vivo colorectal cancer models

Гончарова¹,

Khodakova²,

Volkova³

et al. 2022

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Purpose of the study. The investigation is aimed to provide a systematic comparison of different contrasting methods for in vivo micro-CT diagnostic of orthotopic colorectal cancer models extracted by ortotopic implantation into the caecum of immunocompromised mice BALB/c Nude lines.Materials and methods. BALB/c Nude (N = 25) female mice were implanted by transplanted human colorectal cancer strain into the cecum. 20 days after the implantation mice were administered with iodine-based contrast agent Optiray by means of different administration method (intravenously, per os, intraperitoneally, per rectum) and micro-CT scans have been registered via Quantum GX2 tomograph. Measurement of tumor nodes was performed both by means of estimation from micro-CT images via RadiAnt DICOM Viewer software and by means of explicit measurements using calipers upon laparotomy and posthumously. At the last stage of the study, the animals were euthanized by cervical dislocation. The tumors were excised, measured with a caliper and placed in 10 % formalin for the standard histological analysis according to the standard methods.Results. The average volumes of tumor xenografts in animals with intravenous, oral, and intraperitoneal contrast administration measured at micro-CT were 53.7 ± 5.2 mm3, 52.7 ± 6.4 mm3 and 63.6 ± 5.6 mm3 respectively; measured at laparotomy – 43.0 ± 5.5 mm3, 44.5 ± 5.4 mm3 and 58.5 ± 5.5 mm3 respectively; measured post-mortem – 55.2 ± 6.6 mm3, 53.2 ± 8.8 mm3 and 65.9 ± 3.8 mm3 respectively. The average volumes of tumor xenografts isolated post-mortem in these groups were comparable with the values shown at micro-CT, but larger than the volumes measured at laparotomy.Conclusion. The results obtained demonstrated that intravenous, peroral and intraperitoneal administration techniques provide the best visualization of laboratory rodents pathological tissue upon in vivo micro-CT diagnostics and thus are preferred.

show abstract

A comparative study of different contrast administration routes efficiency performed on in vivo colorectal cancer models

Гончарова¹,

Khodakova²,

Volkova³

et al. 2022

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

show abstract

Modern approaches to glioblastoma therapy

Kuznetsova¹,

Gurova²,

Гончарова³

et al. 2023

jour

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most malignant and the most common primary tumor of the central nervous system. During the last several years GBM has been classified and managed according to the World Health Organization (WHO) criteria which subdivide it into primary and secondary GBM. As it is suggested, GBM originates from glial cells and has a diffuse growth pattern, but its etiology and pathophysiology are poorly investigated up to date. Its rapid progression and anatomical location in the brain often limits the effectiveness of therapeutic interventions. Despite all scientific and technological advances, GBM remains an incurable disease with a median survival of approximately 18 months. Standard treatment options involving maximal safe resection of the tumor followed with radiotherapy and chemotherapy do not provide satisfactory Results.Better understanding of the molecular pathology of GBM and its associated signaling pathways has opened up possibilities for new treatments for newly diagnosed and relapsing tumors. A multitargeted therapeutic approach using compounds capable of inhibiting more than one specific molecular target is a promising alternative to conventional therapies.Currently, specialists study such innovative treatment options as small molecule inhibitors aimed at signaling pathway disruptions, immunotherapy, including checkpoint inhibitors, oncolytic vaccines, CAR T-cell therapy, and drug delivery systems. In terms of an innovative approach, the elaboration of targeted drug delivery systems is of particular interest, since this strategy looks the most promising due to its ability to increase the bioavailability and effectiveness of both standard and newly tested agents. This review discusses results of preclinical and clinical studies of innovative therapeutic approaches, their advantages and disadvantages. An interdisciplinary approach is expected to be able to combine the results of cutting-edge research in this area and to provide novel promising therapeutic strategies for patients with GBM.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Study of Antitumor Efficacy of Bortezomib Combined With Temozolomide in Subcutaneous PDX Models of Human Glioblastoma

Cited by 2 publications

References 7 publications

A comparative study of different contrast administration routes efficiency performed on in vivo colorectal cancer models

A comparative study of different contrast administration routes efficiency performed on in vivo colorectal cancer models

Modern approaches to glioblastoma therapy

Contact Info

Product

Resources

About